Biotech firm Ocugen's Q3 revenue beats expectations

Ocugen

05/11/2025 11:37

Overview

Ocugen Q3 revenue beats analyst expectations, reaching $1.75 mln

Company closed $20 mln direct offering, extending cash runway into 2026

Executed licensing agreement with Kwangdong for OCU400 rights in South Korea

Outlook

Ocugen plans BLA filing for OCU410ST in 1H 2027

Company expects interim data for OCU410ST mid-2026

Ocugen's cash runway extended into 2027 with warrant exercise

Result Drivers

Total operating expenses for the three months ended September 30, 2025 were $19.4 million and included research and development expenses of $11.2 million and general and administrative expenses of $8.2 million

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$1.75 mln
$550,000 (4 Analysts)
Q3 Net Income
-$20.05 mln
Q3 Operating Expenses
$19.37 mln
Q3 Profit From Operations
-$17.62 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Ocugen Inc is $7.00, about 79.6% above its November 4 closing price of $1.43

Press Release: ID:nGNX1hv8mM

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)